![PDF) Assessing libraries and library users and use: proceedings of the 13th international conference Libraries in the Digital Age (LIDA), Zadar, 16-20 June 2014 | Boris Bosančić - Academia.edu PDF) Assessing libraries and library users and use: proceedings of the 13th international conference Libraries in the Digital Age (LIDA), Zadar, 16-20 June 2014 | Boris Bosančić - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/75128733/mini_magick20211124-15617-cy4jzj.png?1637826879)
PDF) Assessing libraries and library users and use: proceedings of the 13th international conference Libraries in the Digital Age (LIDA), Zadar, 16-20 June 2014 | Boris Bosančić - Academia.edu
![Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association | Circulation Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association | Circulation](https://www.ahajournals.org/cms/asset/d2834791-6ad1-4e42-b211-da7a339074cc/cir.0000000000000979.fig05.gif)
Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association | Circulation
![SciELO - Brasil - Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021 Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021 SciELO - Brasil - Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021 Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021](https://minio.scielo.br/documentstore/1678-4170/ZNHQMyQhkNzRm3srCTt4Fcz/feccb52f4fd321373c00366c3175a40608e8162f.jpg)
SciELO - Brasil - Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021 Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021
![Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/e11e5eb6-8896-4cea-afb3-466970923e53/gr1_lrg.gif)
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology
![Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life | Blood Cancer Journal Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-021-00432-4/MediaObjects/41408_2021_432_Fig1_HTML.png)
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life | Blood Cancer Journal
![Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients | British Journal of Cancer Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01608-2/MediaObjects/41416_2021_1608_Fig1_HTML.png)
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients | British Journal of Cancer
![Emerging Epigenetic‐Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment - Zhang - Advanced Science - Wiley Online Library Emerging Epigenetic‐Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment - Zhang - Advanced Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/3f7fc86e-4c46-4606-85f4-1cddd2b2843d/advs4963-fig-0001-m.jpg)
Emerging Epigenetic‐Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment - Zhang - Advanced Science - Wiley Online Library
Relationship between Longitudinal Continuity of Primary Care and Likelihood of Death: Analysis of National Insurance Data | PLOS ONE
![Frontiers | Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies Frontiers | Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies](https://www.frontiersin.org/files/Articles/851825/fbioe-10-851825-HTML/image_m/fbioe-10-851825-g001.jpg)
Frontiers | Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort | PLOS ONE
Hydrology and water management in the humid tropics: proceedings of the Second International Colloquium, 22-26 March 1999, Panama, Republic of Panama
![Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review - McCaughan - 2022 - British Journal of Haematology - Wiley Online Library Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review - McCaughan - 2022 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d7f8e02d-d418-459e-9da8-35591b28c4e4/bjh18295-fig-0001-m.jpg)